Identificado primeiro problema na Stayaway Covid

Identificado primeiro problema na aplicação Stayaway Covid. Código já está a ser escrutinado: Francisco Cruz, elemento do INESC TEC que faz parte da equipa de desenvolvimento da aplicação, defende-se das críticas. “Dizem que não há testes de todo, mas isso não é verdade. Só a parte da interface gráfica é que não tem testes”, sublinha.

Bernard-Henri Lévy: “Las medidas excepcionales por el coronavirus son peligrosas”

Bernard-Henri Lévy: “Las medidas excepcionales por el coronavirus son peligrosas”: Una cosa es que el confinamiento fuera ineludible desde un punto de vista sanitario. Pero el regocijo ante esa reclusión impuesta que muchos han asumido de manera complaciente, es “una enorme indecencia” y “un insulto para los que no tenían dónde confinarse”, según Bernard-Henri Lévy

Perguntas & Respostas sobre Burnout

Perguntas & Respostas sobre burnout: O burnout ou síndrome de esgotamento profissional é um tipo específico de stresse ocupacional, ou seja, de stresse provocado pelo trabalho. Caracteriza-se, sobretudo, pela exaustão emocional e pela diminuição do envolvimento pessoal no trabalho.

Russia plans to use a vaccine that doesn't yet meet WHO standards

Russia plans to use a vaccine that doesn't yet meet WHO standards: Though Russian government officials are crowing about the achievement, the Gamaleya Research Institute scientists behind the vaccine have yet to publish data showing their vaccine works. According to the World Health Organization (WHO), Russia’s Gamaleya Research Institute is still in the early phases of testing.

Scientific standards endorsed by the WHO ensure that any new vaccine goes through three phases of human trials before it’s approved. The first stage, typically involving fewer than a hundred participants, evaluates safety; the second provides preliminary data about efficacy. The third and final stage, which usually involves tens of thousands of participants, provides more safety information and determines whether the vaccine is effective.

Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020

Goldman Sachs says investors are underestimating the chance of a COVID-19 vaccine in 2020, an event that could push the S&P 500 11% higher: "We agree that there is now a good chance that at least one vaccine will be FDA-approved by the end of November and broadly distributed by the middle of 2021," they added.

5 coronavirus face mask myths under the microscope

5 coronavirus face mask myths under the microscope: Experts point to many good reasons to wear one but few good reasons not to.

Vitamin D & Covid-19

Vitamin D & Covid-19: The authors see sufficient scientific plausibility that with a good vitamin D level many corona deaths could still be alive today.